Host: Fortunato Ciardiello, MD, PhD 

 Host: Jenny Seligmann, MBChB, PhD 


 
 This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Fortunato Ciardiello, MD, PhD 

 Host: Jenny Seligmann, MBChB, PhD 


 
 This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Share Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond

Sign up to save your podcasts

Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond

Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond